%PDF-1.4
%
33 0 obj
<>
endobj
30 0 obj
<>
endobj
103 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-12-14T13:07:06Z
2024-03-29T03:58:01-07:00
QuarkXPressª: AdobePS 8.6 (219)
2024-03-29T03:58:01-07:00
application/pdf
Heather
2002-90.oct02
uuid:ed72a1aa-1dd1-11b2-0a00-7f09278d5b00
uuid:ed72a1ad-1dd1-11b2-0a00-1e0000000000
endstream
endobj
19 0 obj
<>
endobj
20 0 obj
<>
endobj
34 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
1 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
4 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
12 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
15 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
122 0 obj
[126 0 R]
endobj
123 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.06 612 -792 re
W n
BT
/CS0 cs 0 0 0 1 scn
/GS1 gs
/TT0 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 61 714.5293 Tm
[(7.)-875.1 (Gonzalez-Gay MA, Garcia-Porrua C, Salvarani C, Olivieri I,)]TJ
0 Tc 1.675 -1.25 Td
[(Hunder GG. )17.7 (The spectrum of conditions mimicking polymyalgia)]TJ
0 -1.25 TD
(rheumatica in Northwestern Spain. J Rheumatol 2000;27:2179-84.)Tj
-0.00011 Tc -1.675 -1.25 Td
[(8.)-875.1 (Bahlas S, Ramos-Remus C, Davis P)110.7 (.)-0.1 ( Clinical outcome of 149)]TJ
0 Tc 1.675 -1.25 Td
(patients with polymyalgia rheumatica and giant cell arteritis. J)Tj
T*
(Rheumatol 1998;25:99-104.)Tj
-0.00011 Tc -1.675 -1.25 Td
[(9.)-875.1 (Haga HJ, Eide GE, Brun J, Johansen )54.8 (A, Langmark F)79.7 (.)-0.1 ( Cancer in)]TJ
0 Tc 1.675 -1.25 Td
(association with polymyalgia rheumatica and temporal arteritis. J)Tj
T*
(Rheumatol 1993;20:1335-9.)Tj
-2.175 -1.25 Td
[(10.)-875 (Huston KA, Hunder CG, Lie JT)74 (, Kennedy RH, Elveback LR.)]TJ
2.175 -1.25 Td
[(T)69.8 (emporal arteritis: )54.8 (A)-219.8 (25-year epidemiological, clinical and )]TJ
T*
[(pathological study)64.9 (. )54.9 (Ann Intern Med 1978;88:162-7.)]TJ
-0.00011 Tc -2.1381 -1.25 Td
[(1)36.8 (1)-0.1 (.)-875.1 (Boesen P)110.7 (, Freiesleben F)79.7 (, Sorensen S. Giant cell arteritis, temporal)]TJ
0 Tc 2.1381 -1.25 Td
[(arteritis, and polymyalgia rheumatica in a Danish county)64.9 (. )54.9 (Arthritis)]TJ
T*
(Rheum 1987;30:294-9.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(12.)-875.1 (Gran JT)73.9 (, Myklebust G, )17.7 (W)39.7 (ilsgaard )17.7 (T)73.9 (,)-0.1 ( Jacobsen BK. Survival in)]TJ
0 Tc 2.175 -1.25 Td
(polymyalgia rheumatica and temporal arteritis: a study of 398 cases)Tj
T*
(and matched population controls. Rheumatology 2001;40:1238-42.)Tj
-2.175 -1.25 Td
[(13.)-875 (Myklebust G, Gran JT)74 (. )54.8 (A)-219.8 (prospective study of 287 patients with)]TJ
2.175 -1.25 Td
(polymyalgia rheumatica and temporal arteritis: clinical and )Tj
T*
(laboratory manifestations at onset of disease and at the time of)Tj
T*
[(diagnosis. Br J Rheumatol 1996;35:1)36.9 (161-8.)]TJ
-2.175 -1.25 Td
[(14.)-875 (Gran JT)74 (, Myklebust G. )17.7 (The incidence and clinical characteristics of)]TJ
2.175 -1.25 Td
(peripheral arthritis in polymyalgia rheumatica and temporal)Tj
T*
(arteritis: a prospective study of 231 cases. Rheumatology)Tj
0 Tw T*
(2000;39:283-7.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(15.)-875.1 (Bird HA, Esselinckx )17.7 (W)91.7 (,)-0.1 ( Dixon )54.8 (ASTJ, Mowat )54.8 (AG, )17.7 (W)79.7 (ood PHN. )54.8 (An)]TJ
0 Tc 2.175 -1.25 Td
[(evaluation of criteria for polymyalgia rheumatica. )54.8 (Ann Rheum Dis)]TJ
0 Tw T*
(1979;38:434-9.)Tj
0.02499 Tw -2.175 -1.25 Td
[(16.)-875 (Hamrin B. Polymyalgia rheumatica. )54.9 (Acta Med Scand 1972;533)]TJ
0 Tw 2.175 -1.25 Td
(Suppl:1-13.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(17.)-875.1 (Chuang )17.7 (T)91.7 (-)0.4 (Y)128.8 (, Hunder GG, Ilstrup DM, Kurland L)91.7 (T)73.9 (. Polymyalgia)]TJ
0 Tc 2.175 -1.25 Td
[(rheumatica. )54.8 (A)-219.8 (10-year epidemiologic and clinical study)64.9 (. )54.8 (Ann Intern)]TJ
T*
(Med 1982;97:672-80.)Tj
-2.175 -1.25 Td
[(18.)-875 (Hunder GG, Bloch DA, Michel BA, et al. )17.7 (The )54.8 (American College of)]TJ
2.175 -1.25 Td
(Rheumatology 1990 criteria for the classification of giant cell)Tj
T*
[(arteritis. )54.9 (Arthritis Rheum 1990;33:1)36.9 (122-8.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(19.)-875.1 (SAS/ST)79.7 (A)111 (T)-257.3 (user)-37 (\222)55.1 (s)-0.1 ( guide. )17.7 (V)111 (ersion 6, 4th ed. Gary: SAS Institute;)]TJ
0 Tc 0 Tw 2.175 -1.25 Td
(1990.)Tj
0.0249 Tw -2.175 -1.25 Td
[(20.)-875 (von Knorring J, Somer )17.7 (T)74 (. Malignancy in association with)]TJ
2.175 -1.25 Td
(polymyalgia rheumatica and temporal arteritis. Scand J Rheumatol)Tj
0 Tw T*
(1974;3:129-35.)Tj
0.02499 Tw -2.175 -1.25 Td
[(21.)-875 (Mackenzie )54.9 (AH. )17.8 (The polymyalgia rheumatica syndrome. Geriatrics)]TJ
0 Tw 2.175 -1.25 Td
(1969;24:158-66.)Tj
0.0249 Tw -2.175 -1.25 Td
[(22.)-875 (Hunder G, Disney )17.7 (T)74 (, Emmerson L. Polymyalgia rheumatica. Mayo)]TJ
2.175 -1.25 Td
(Clin Proc 1969;44:849-75.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(23.)-875.1 (Andersson R, Malmvall B-E, Bengtsson B-\305. Long-term survival)]TJ
0 Tc 2.175 -1.25 Td
(in giant cell arteritis including temporal arteritis and polymyalgia)Tj
T*
[(rheumatica. )54.9 (Acta Med Scand 1986;220:361-4.)]TJ
30.825 60 Td
[(24.)-750 (Salvarani C, Macchioni PL, )17.8 (T)69.8 (artoni PL, et al. Polymyalgia)]TJ
2.175 -1.25 Td
(rheumatica and giant cell arteritis: a 5-year epidemiological and)Tj
T*
[(clinical study in Reggio, Italy)64.9 (. Clin Exp Rheumatol 1987;5:205-15.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(25.)-750.1 (Schaufelber)17.7 (ger C, Bengtsson B-\305, )54.8 (Andersson R. Epidemiology and)]TJ
0 Tc 2.175 -1.25 Td
(mortality in 220 patients with polymyalgia rheumatica.)Tj
T*
(Br J Rheumatol 1995;34:261-4.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(26.)-750.1 (Matteson EL, Gold KN, Bloch DA, Hunder GG. Long-term)]TJ
0 Tc 2.175 -1.25 Td
[(survival of patients with giant cell arteritis in the )54.9 (American College)]TJ
T*
(of Rheumatology giant cell arteritis classification criteria cohort.)Tj
T*
(Am J Med 1996;100:193-6.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(27.)-750.1 (Gonzalez-Gay MA, Garcia-Porrura C, )17.7 (V\341zquez-Caruncho M,)]TJ
0 Tc 2.175 -1.25 Td
[(Dababneh )54.8 (A, Hajeer )54.8 (A, Ollier )17.7 (WER. )17.7 (The spectrum of polymyalgia)]TJ
T*
(rheumatica in Northwestern Spain: incidence and analysis of)Tj
T*
[(variables associated with relapse in a 10 year study)64.9 (. J Rheumatol)]TJ
0 Tw T*
(1999;26:1326-32.)Tj
0.02499 Tw -2.175 -1.25 Td
[(28.)-750 (Gonzalez-Gay MA, Blanco R, )54.9 (Abraira )17.8 (V)129.1 (, et al. Giant cell arteritis in)]TJ
2.175 -1.25 Td
[(Lugo, Spain, is associated with low longterm mortality)64.9 (. )]TJ
T*
(J Rheumatol 1997;24:2171-6.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(29.)-750.1 (Shimamoto )36.8 (Y)129.1 (, Matsunaga C, Suga K, Fukushima N, Nomura K,)]TJ
0 Tc 2.175 -1.25 Td
[(Y)100.1 (amagushi M. )54.8 (A)-219.8 (human )17.7 (T)91.8 (-)0.1 (cell lymphotropic virus type I carrier)]TJ
T*
(with temporal arteritis terminating in acute myelogenous leukemia.)Tj
T*
(Scand J Rheumatol 1994;23:151-3.)Tj
-2.175 -1.25 Td
[(30.)-750 (Gabriel S, Conn D, Phyliky R, Pittelkow M, Scott R. )17.8 (V)111.1 (asculitis in)]TJ
2.175 -1.25 Td
(hairy cell leukemia: review of literature and consideration of)Tj
T*
[(possible pathogenic mechanisms. J Rheumatol 1986;13:1)36.9 (167-72.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(31.)-750.1 (Greer JM, Longley S, Edwards NL, Elfenbein GJ, Panush RS.)]TJ
0 Tc 2.175 -1.25 Td
[(V)111.1 (asculitis associated with malignancy: experience with 13 patients)]TJ
T*
[(and literature review)64.9 (. Medicine 1988;67:222-30.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(32.)-750.1 (Case records of the Massachusetts General Hospital. N Engl J Med)]TJ
0 Tc 0 Tw 2.175 -1.25 Td
(1990;322:1656-65.)Tj
0.02499 Tw -2.175 -1.25 Td
[(33.)-750 (Caldwell DS, McCallum RM. Rheumatological manifestations of)]TJ
2.175 -1.25 Td
[(cancer)54.9 (. Med Clin North )54.9 (Am 1986;70:385-417.)]TJ
-2.175 -1.25 Td
[(34.)-750 (Kalra L, Delamere JP)110.8 (. L)54.9 (ymphoreticular malignancy and monoclonal)]TJ
2.175 -1.25 Td
(gammopathy presenting as polymyalgia rheumatica.)Tj
T*
(Br J Rheumatol 1987;26:458-9.)Tj
-2.175 -1.25 Td
[(35.)-750 (Kyle RA. Monoclonal gammopathy of undetermined significance)]TJ
2.175 -1.25 Td
[(\(MGUS\): a review)64.9 (. Clin Haematol 1982;2:123-50.)]TJ
-2.175 -1.25 Td
[(36.)-750 (Lie JT)74 (. Simultaneous clinical manifestations of malignancy and)]TJ
2.175 -1.25 Td
(giant cell temporal arteritis in a young woman. J Rheumatol)Tj
0 Tw T*
(1995;22:367-9.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(37.)-750.1 (Montanaro M, Bizzari F)79.7 (. Non-Hodgkin\222)54.8 (s lymphoma and subsequent)]TJ
0 Tc 2.175 -1.25 Td
(acute lymphoblastic leukaemia in a patient with polymyalgia)Tj
T*
(rheumatica. Br J Rheumatol 1992;31:277-8.)Tj
-2.175 -1.25 Td
[(38.)-750 (T)69.8 (abata M, Kobayashi )17.8 (T)74 (. Polymyalgia rheumatica and thyroid )]TJ
2.175 -1.25 Td
(papillary carcinoma. Intern Med 1994;33:41-4.)Tj
ET
/CS0 CS 0 0 0 1 SCN
54 54 m
558 54 l
S
BT
/TT1 1 Tf
8 0 0 8 54.5 35.9844 Tm
[(Myklebust, et al: Cancer in PMR and T)74 (A)]TJ
0 Tw 60.9375 -0.0313 Td
(2147)Tj
ET
0 0 0 0 scn
/GS0 gs
103.79 57.82 407.5 -10.83 re
f*
0.5 w
103.79 57.82 407.5 -10.83 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_0 8 Tf
120.092 51 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2002. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_1 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 29, 2024 from )Tj
ET
endstream
endobj
75 0 obj
<>
endobj
109 0 obj
<>
endobj
41 0 obj
<>
endobj
36 0 obj
<>
endobj
38 0 obj
<>
endobj
70 0 obj
<>stream
HV lޛ]1v93)9L.>0@V-HJ RQbp(M&TP PG"
" D@~6|o.vqz&}-TFLfĺbUͬxEFp$ 9EeM 6s4PfND;s+,
Jeq *%P!UXX'ߡW0WU9uK_UJ5'Y- $jT Αn
wL߷RB b1oݑvA!= iw 9r]*8KPM4/\?E؍#8ؙi{8)>Qk-#=Xco C̷1uy9&q-s"RtD#xz ;M^!GX`(FG5XDv4@}vFk<,1qOLV7kht`bܩ59&\Qb*28,HV+{uɬ̳&a qOtjx
wD&E"SsLVC;UQWMֵ0N8Y>D>9
X$
{ȶc?3ь{x 4b+qAF8iaQ*Sj
}oBk):iD\ܫ%=r؆yvos}q_
bhm<$(+9RU®Z,bxS!߉Sq!}r\,W)yF~-G%RIQ\uZԢZVr}x;/RhZ:trZVUm-6[
p%#0ؑvu4rMs؛s3;٧Ox2Sy\af?>"$ Tֹ3sŌF0I@1MLe\渒cxYnnqP\WQe&;3Bpx*d\.ߑʍMIr!}tm"#MU@4#GmPo
a3iK-~fi<1 rg^C7z(zuQZM3ȸ\н y)^]qp۸3!np}[;NL4fg#/SR3ϛr3M[l0a3g#\ӑ,;wgjFTQ3@E33_oJx>ZyW*Ҕ,ʑ-ȍ3\V32m6$J
-HcQg&&,rIL4ZQI>edwwBp¢?w蝟ָ3td<Еemv.q5qՄ
xYzN >_9ЌO`f` Zj h4xZh8Rc~Phmfd9S6ڐ;L2bt3B>(ź\vV6x0Y;똑BSmG[SHo4W,H{i[>qC]ZB4@hkhgD""O!}`_T|erM8BPW@rQ^a7s^.[l{R1)ԅ$I)HY#0F'Spxؘ([\Wyki[xYg5+[G㨳mR_jٺx:OP>XK6tbn~sWRwe59p/!/d²sw3f6EM'^q&SRJoW'!5#vvΏr
o1~J-TdO
~Fǔ"&R'R